Taurine in Peripartum Cardiomyopathy

Peripartum Cardiomyopathy Clinical Trial

Official title:

Taurine for Early Left Ventricular Recovery in Peripartum Cardiomyopathy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03907267
• Other study ID #: AS1755
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: January 1, 2015
• Est. completion date: January 1, 2020

Study information

• Verified date: January 2020
• Source: Ain Shams University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Taurine as an adjunct for early left ventricular recovery in peripartum cardiomyopathy

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: January 1, 2020
• Est. primary completion date: December 1, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Peripartum Cardiomyopathy

Exclusion Criteria:

• Other identifiable cause for heart failure

• low LVEF = 25%

• sepsis

• autoimmune disease

• severe chronic disease

• malignancy

Related Conditions & MeSH terms

• Cardiomyopathies
• Peripartum Cardiomyopathy

Intervention

Drug:
• Taurine Solution
Taurine Solution

Dietary Supplement:
• Normal Saline
Normal Saline

Locations

Country	Name	City	State
Egypt	Ain Shams University Maternity Hospital	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	improvement of the left ventricular ejection fraction >10 %	improvement of the left ventricular ejection fraction >10 %	1 week